Home
 

> About Asthmatx
> Career Opportunities
> News & Events
> Media & Investor Relations

Our commitment to
excellence.


By radically changing the standard of care, Asthmatx will be the world leader in device-based solutions for patients with asthma.

FAQ
What is Asthma?
Asthma is a common disease in which the airways in the lung become inflamed, excess airway mucus is produced, and airways narrow when muscles within the airway walls contract.

News & Events


Featured Articles
 
American Journal of Respiratory and Critical Care Medicine  
  January 12, 2010: Asthmatx Pivotal Trial Manuscript for Bronchial Thermoplasty Published in the American Journal of Respiratory and Critical Care Medicine
Click Here To Read Full Story

Asthmatx, Inc. Announcement  
  October 28, 2009: Asthmatx Receives FDA Advisory Panel Recommendation for Approvable with Conditions for Bronchial Thermoplasty with the Alair® System for Severe Asthma
Click Here To Read Full Story



News Releases


Corporate Releases

Archived News




Corporate Releases

January 12, 2010: Asthmatx Pivotal Trial Manuscript for Bronchial Thermoplasty Published in the American Journal of Respiratory and Critical Care Medicine
Click Here To Read Full Story

January 5, 2010: Asthmatx to Present at 28th Annual JPMorgan Healthcare Conference
Click Here To Read Full Story

October 28, 2009: Asthmatx Receives FDA Advisory Panel Recommendation for Approvable with Conditions for Bronchial Thermoplasty with the Alair® System for Severe Asthma
Click Here To Read Full Story

May 18, 2009: Pivotal Data Show Bronchial Thermoplasty Can Improve Quality of Life and Reduce Asthma Attacks and Emergency Room Visits for Adults with Severe Asthma
Click Here To Read Full Story

May 6, 2009: Pivotal Data on Bronchial Thermoplasty from the Asthma Intervention Research 2 (AIR2) Trial to be Presented at ATS 2009
Click Here To Read Full Story

January 12, 2009: Asthmatx Seeks FDA Approval of New Device-Based Procedure for Severe Asthma
Click Here To Read Full Story


Back to News Releases


Archived News

February 11, 2008: One Year Results of Bronchial Thermoplasty in Refractory Asthma
Click Here To Read Full Story

May 23, 2007: Bronchial Thermoplasty May Allow Severe Asthma Patients to Wean Off Oral Corticosteroids
Click Here To Read Full Story

May 22, 2007: A New Outpatient Procedure for Asthma
Click Here To Read Full Story

May 21, 2007: Asthmatx Completes Enrollment in Pivotal Study of Bronchial Thermoplasty: Milestone Reached in Advancement of Bronchial Thermoplasty, an Innovative Non-drug Procedure for Asthma
Click Here To Read Full Story

May 15, 2007: Asthmatx Announces $50 Million Investment by Olympus Medical Systems Corp.
Click Here To Read Full Story

March 29, 2007: New England Journal of Medicine Report Shows Improved Asthma Control One Year Following a New Outpatient Procedure for Asthma
Click Here To Read Full Story

February 24, 2007: New Outpatient Procedure for Severe Asthma Shows Positive Results
Click Here To Read Full Story

December 27, 2006: Bronchial Thermoplasty Named One of the "Top Ten Medical Innovations for 2007" by the Cleveland Clinic
Click Here To Read Full Story

November 8, 2006: Asthmatx, Inc.'s Alair® System Named "Best of 2006" by Popular Science
Click Here To Read Full Story

September 19, 2006: Positive Patient Reported Outcomes Following Bronchial Thermoplasty for Asthma
Click Here To Read Full Story

May 22, 2006: Results of a Novel Investigational Asthma Treatment Reported at the American Thoracic Society Conference
Click Here To Read Full Story

May 1, 2006: Encouraging Results Reported on New Investigational Asthma Treatment
Click Here To Read Full Story

April 17, 2006: First Patient in the US is Treated with Investigational Outpatient Procedure for Asthma
Click Here To Read Full Story

January 9, 2006: Outpatient Procedure for Asthma
Click Here To Read Full Story


Back to News Releases



CAUTION: The Alair® System is an Investigational device. It is limited by United States law to investigational use. To be used by Qualified Investigators only.